• Our People
  • Global Presence
  • Regions
    • Asia
    • Europe
    • Americas
  • Offices
    • Canada
      • Ottawa
      • Toronto
    • China
      • Beijing
      • Hong Kong
    • Luxembourg
    • Malaysia
    • Singapore
    • UK
      • Aberdeen
      • Birmingham
      • Cambridge
      • Edinburgh
      • Glasgow
      • London
      • Manchester
      • Oxford
  • Client liaison
    • Japan
    • Korea
  • Expertise
  • Services
    • Patents
    • Brands & Trade Marks
    • Designs
    • Litigation & Dispute Resolution
    • Commercial IP & Contracts
    • Due Diligence
    • Freedom to Operate
    • EPO Patent Oppositions
    • European Patent Validations
    • Anti-counterfeiting
    • Open Source & Third Party Code
  • Sectors
    • Digital Transformation
      • 3D Printing
      • Artificial Intelligence
      • Blockchain
      • Data & Connectivity
      • Extended Reality
      • Industry 4.0
    • Energy & Environment
    • Life Sciences
    • Agritech
    • Medical Technologies
    • Chemistry
    • Transport
    • Entertainment & Creative Industries
    • Food & Drink
    • Fashion & Retail
    • Universities & Research Bodies
    • Start-ups & Spin-outs
      • Creating value for start-ups
      • The IP driven start-up
    • Financial Services
  • About Us
    • Working with us
    • Awards
    • Corporate & Social Responsibility
    • Diversity & Inclusion
    • Careers
  • Insights
    • Articles
    • News
    • Events
    • Resources
    • Unified Patent Court hub
    • Beyond Brexit: European trade mark hub
    • M&C Reacts
  • Contact Us
Marks & Clerk logo
Marks & Clerk logo
Contact Us
Language
English
Our People
Global Presence
Regions
  • Asia
  • Europe
  • Americas
Offices
  • Canada
    • Ottawa
    • Toronto
  • China
    • Beijing
    • Hong Kong
  • Luxembourg
  • Malaysia
  • Singapore
  • UK
    • Aberdeen
    • Birmingham
    • Cambridge
    • Edinburgh
    • Glasgow
    • London
    • Manchester
    • Oxford
Client liaison
  • Japan
  • Korea
Expertise
Services
  • Patents
  • Brands & Trade Marks
  • Designs
  • Litigation & Dispute Resolution
  • Commercial IP & Contracts
  • Due Diligence
  • Freedom to Operate
  • EPO Patent Oppositions
  • European Patent Validations
  • Anti-counterfeiting
  • Open Source & Third Party Code
Sectors
  • Digital Transformation
    • 3D Printing
    • Artificial Intelligence
    • Blockchain
    • Data & Connectivity
    • Extended Reality
    • Industry 4.0
  • Energy & Environment
  • Life Sciences
  • Agritech
  • Medical Technologies
  • Chemistry
  • Transport
  • Entertainment & Creative Industries
  • Food & Drink
  • Fashion & Retail
  • Universities & Research Bodies
  • Start-ups & Spin-outs
    • Creating value for start-ups
    • The IP driven start-up
  • Financial Services
About Us
  • Working with us
  • Awards
  • Corporate & Social Responsibility
  • Diversity & Inclusion
  • Careers
Insights
  • Articles
  • News
  • Events
  • Resources
  • Unified Patent Court hub
  • Beyond Brexit: European trade mark hub
  • M&C Reacts

Biomedical businesses booming in Cambridge

Biomedicine in Cambridge
04 April 2022
Jasmine Percival
Print
Share

Marks & Clerk was were delighted to attend the launch event of the 2022 Cambridge Biomedical Cluster map, an insightful project undertaken by letscellit.com in collaboration with Brockton Everlast. The cluster map highlights the breadth and depth of the biomedical landscape of Cambridge, with a host of diverse biomedical companies having a base here, as well as a world leading university, hospitals and research institutes.

The map shows that the Cambridge Biomedical Cluster is an epicentre for new businesses and innovation, with 52% of the cluster being classed as micro-enterprises. However, Cambridge is not short of small – medium and large enterprises, hosting 7 of the world’s top pharmaceutical companies, offering a unique hub of biomedical expertise and innovation, with opportunities for collaboration. The 397 biomedical companies forming the cluster shows that Cambridge remains a key player in the biomedical supply chain. The cluster includes a range of companies that develop biomedical instrumentation, research tools and reagents, contributing to Cambridge’s position as a leader in biomedical research and innovation. Cambridge is also a major player in therapeutics, with a wide range of therapeutic companies undertaking leading R&D being based here, with a strong force of enterprises focusing on oncology therapeutics.

It is particularly exciting to see from the updated 2022 Cambridge Biomedical Cluster map that there was a 49% increase in companies created in the 2010’s compared to the previous decade, and an average of 1 new company per month in the last 2 years. This highlights that the biomedical landscape in Cambridge is expanding. In particular, there has been growth in enterprises working in the area of medical devices. This is a rapidly moving field bringing together expertise from different areas, with Cambridge as a hub of technical excellence as well as biomedical excellence. We anticipate some breakthrough technologies will arise from growth in this area.

At Marks & Clerk, we have worked with several companies on the cluster map and have helped them protect their IP assets. We have in-depth knowledge across biomedical technologies including drug delivery, surgical equipment, diagnostic methods, small molecules and immunology. In addition to our vast expertise in biomedical technologies we have attorneys with expertise across emerging areas at the forefront of development of new medical technologies such as AI and machine learning and personalised medicine.

If you require intellectual property advice, please get in touch.

Next Story
  • Preliminary position on priority published
  • International patent insights on quantum computing
  • InterDigital v Lenovo: The latest FRAND judgment
  • Cambridge: City of Innovation - The 'beer summit' that generated a genomic revolution
  • IP protection in collaborations: "Just Do It"
More insights

Latest Insights

Chemistry
Article
- 24 March 2023

Preliminary position on priority published

As we reported in early 2022, the Enlarged Board of Appeal of the EPO are considering two pending referrals (G1/22 and G2/22) regarding the question of entitlement to priority. A hearing has now been set for 26 May 2023, and the Enlarged Board have now issued a preliminary opinion setting out the points to be discussed.
Read more
Quantum computing
Article
- 22 March 2023

International patent insights on quantum computing

The latest patent insight report from the European Patent Office (EPO) looks at the trends in patent filings for quantum computing, and has uncovered some interesting findings.
Read more
Article
- 22 March 2023

InterDigital v Lenovo: The latest FRAND judgment

On 16 March 2023, Mr Justice Mellor handed down the latest FRAND judgment: InterDigital v Lenovo. The case concerned a dispute between InterDigital and Lenovo as to the terms on which Lenovo should take a licence to InterDigital’s portfolio of patents which had been declared essential to the European Telecommunications Standard Institute (ETSI) Standards.
Read more
Marks & Clerk logo (white)
  • Terms & Conditions
  • Privacy Notice
  • Cookies
  • Legal Notices
  • Press Enquiries
  • Lexology
  • Mondaq